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Introduction: Preoperative chemoradiotherapy improves local con-
trol in patients with locoregionally advanced adenocarcinoma of 
the esophagus and gastroesophageal junction (GEJ). Distant failure 
remains common, however, suggesting potential benefit from addi-
tional chemotherapy. This phase II study investigated the addition of 
induction chemotherapy to surgery and adjuvant chemoradiotherapy.
Methods: Patients with cT3-4 or N1 or M1a (American Joint Committee 
on Cancer 6th edition) adenocarcinoma of the esophagus and GEJ were 
eligible. Induction chemotherapy, with epirubicin 50 mg/m2/d, oxali-
platin 130 mg/m2/d, and fluorouracil 200 mg/m2/d continuous infusion 
for 3 weeks, was given every 21 days for three courses, followed by 
surgery. Adjuvant chemoradiotherapy consisted of 50 to 55 Gy at 1.8 
to 2.0 Gy/d and two courses of cisplatin (20 mg/m2/d) and fluorouracil 
(1000 mg/m2/d) during weeks 1 and 4 of radiotherapy.
Results: Between February 2008 and January 2012, 60 evalu-
able patients enrolled. Resection was accomplished in 54 patients 
(90%) and adjuvant chemoradiotherapy in 48 (80%) patients. 
Toxicity included unplanned hospitalization in 18% of patients dur-
ing induction chemotherapy and 19% of patients during adjuvant 
chemoradiotherapy. There was one chemotherapy-related and two 
postoperative deaths. With a median follow-up of 43 months, the 
projected 3-year locoregional control is 88%, distant metastatic 
control 46%, relapse-free survival 41%, and overall survival 47%. 
Symptomatic response to chemotherapy and the percentage of 
remaining viable tumor at surgery proved the strongest predictors of 
survival and distant control.
Conclusions: Chemotherapy, surgery, and adjuvant chemoradiother-
apy are feasible and produce outcomes similar to other multimodal-
ity treatment schedules in locoregionally advanced adenocarcinoma 
of the esophagus and GEJ. Symptomatic response and less residual 
tumor at surgery were associated with improved outcomes.
Key Words: Esophageal cancer, Preoperative chemotherapy, 
Chemoradiotherapy.
(J Thorac Oncol. 2014;9: 1561–1567)
Adenocarcinoma of the distal esophagus and gastroesopha-geal junction (GEJ) is characterized by late presentation, 
early dissemination, and aggressive clinical behavior. Solid 
food dysphagia, the most common presenting symptom, is 
usually not experienced until the disease is locally advanced, 
having breached the esophageal wall or metastasized to 
regional lymph nodes. The prognosis for patients with locore-
gionally advanced disease is poor when patients are treated 
with surgery alone. Both local failure and distant failure are 
common, occurring in approximately 20% to 40% and 50% 
of patients, respectively.1,2 The reported 5-year survivals for 
patients with locoregionally advanced (LRA) disease treated 
with surgery alone range between 5% and 30%.3–6
A number of different adjuvant treatment strategies 
have been investigated in an attempt to improve upon these 
relatively poor outcomes. The optimal management of this 
disease, however, remains unsettled. Preoperative chemora-
diotherapy and to a lesser extent, postoperative chemoradio-
therapy, have been investigated and survival appears to be 
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modestly improved by these tri-modality approaches when 
compared with surgery alone.5–9 In particular, local control is 
excellent, although distant disease recurrence remains com-
mon. This pattern of failure suggests that improved outcomes 
will require greater exposure to systemic therapies. Specific 
concern has been expressed, however, about the potential for 
increased perioperative morbidity and mortality in patients 
receiving more intensive induction chemoradiotherapy.10–13
Perioperative chemotherapy has also been investigated 
in this disease and appears to provide a modest survival ben-
efit when compared with treatment with surgery alone.2,3,9,14 
Multiple chemotherapy regimens and treatment schedules 
have been employed with variable success.2–4 Perhaps the 
most compelling data were reported by Cunningham et al., 
from a phase III trial testing the combination of epirubicin, 
cisplatin, and 5-fluorouracil (5FU) given both before and after 
surgery. This perioperative chemotherapy regimen improved 
the 5-year overall survival (OS) from 23% to 36% (p = 0.009) 
when compared with surgery alone.3
We therefore elected to test the feasibility and tolerance 
of a treatment regimen which incorporated two of these adju-
vant strategies, preoperative chemotherapy and postoperative 
chemoradiation. In this trial, all patients were given induction 
chemotherapy with epirubicin, oxaliplatin, and 5-fluoroura-
cil (EOF), followed by surgical resection and postoperative 
chemoradiotherapy with cisplatin and 5FU. Oxaliplatin was 
used in this induction regimen given the evidence that it is 
more effective and less toxic than cisplatin in the palliative 
setting.15,16 Postoperative chemoradiotherapy utilizing cispla-
tin and 5FU was employed based on our previously published 
data supporting the safety and efficacy of this regimen when 
administered in the adjuvant setting to patients with resected 
locally advanced disease.8
MATERIALS AND METHODS
Study Design
This was a single arm phase II study. Our primary end 
point was the feasibility of surgical resection after induction 
EOF chemotherapy. Secondary end points included the feasibil-
ity of administering postoperative adjuvant chemoradiotherapy 
(CRT) in surgically resected patients, the induction chemo-
therapy response rate, patterns of failure, relapse-free, and OS 
rates. Research support was provided by Sanofi-Aventis. This 
clinical trial was approved and reviewed yearly by the Case 
Comprehensive Cancer Center Institutional Review Board.
Patients
Eligibility for this study required that patients be older 
than or equal to 18 years and have a histologically confirmed 
diagnosis of adenocarcinoma of the esophagus or GEJ. Patients 
with other histologies, including squamous cell carcinoma or 
adenosquamous carcinoma, were not eligible. A clinical stage 
of T3-4 or N1 or M1a (American Joint Committee on Cancer 
6th edition) as assessed by an endoscopic ultrasound (EUS) and 
fused positron emission tomography/computerized tomogra-
phy scan was required. In this version of the staging system, 
M1a disease is defined as involvement of the celiac lymph node 
basin for patients with cancers of the distal esophagus and GEJ. 
An Eastern Cooperative Oncology Group performance status of 
0 to 1, normal bone marrow function (as evidenced by a neutro-
phil count more than 1500/mm3 and a platelet count more than 
100,000/mm3), serum creatinine less than 1.6 mg/dl, total bili-
rubin less than or equal to 1.5 mg/dl, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and alkaline phos-
phatase less than or equal to 3 times the institutional upper limit 
of normal, and adequate pulmonary function (as evidenced by 
a forced expiratory volume in 1 second ≥50% predicted) were 
also required. Pretreatment staging further included an assess-
ment of cardiac function and an audiogram in view of the 
planned administration of cisplatin. All patients reviewed and 
signed written informed consent before entry on study.
Treatment
Patients received three cycles of induction chemo-
therapy with the EOF regimen which consisted of epirubicin 
50 mg/m2 IV on day 1, oxaliplatin 130 mg/m2 IV on day 1, and 
5FU 200 mg/m2/d as a continuous intravenous infusion for 21 
days. Cycles were repeated every 3 weeks. After completion 
of chemotherapy, patients were restaged with EUS and a com-
puterized tomography of the chest, abdomen, and pelvis.
Surgery was scheduled 4 to 5 weeks after the completion 
of chemotherapy. Patients underwent either a transthoracic 
esophagogastrectomy with a cervical esophagogastrostomy or 
a total gastrectomy with a Roux-en-Y esophagojejunostomy, 
usually through a left thoracoabdominal approach. A tempo-
rary feeding jejunostomy tube was placed in all patients for 
postoperative enteral nutritional supplementation.
Adjuvant chemoradiotherapy was initiated between 6 
and 10 weeks postoperatively. External beam radiotherapy 
was delivered to the esophagogastric tumor bed and draining 
lymphatic regions. For tumors of the GEJ and distal esopha-
gus, at-risk regional lymphatics included the lower medias-
tinum and celiac lymph nodes. For mid-esophageal tumors, 
all mediastinal lymph node stations were treated. The total 
dose of radiation was 50 to 55 Gy administered in 180 to 200 
cGy daily fractions using three-dimensional conformal fields. 
Concurrent with radiotherapy, patients received two cycles of 
cisplatin and fluorouracil during the first and fourth weeks of 
treatment. Both agents were administered as continuous intra-
venous infusions over the course of 96 hours on a dedicated 
inpatient chemotherapy service. The total cisplatin dose per 
cycle was 80 mg/m2 administered at 20 mg/m2/d. The total 5FU 
dose per cycle was 4000 mg/m2 administered at 1000 mg/m2/d.
After the completion of treatment, patients were fol-
lowed clinically every 8 to 12 weeks for the first 3 years and 
then less often subsequently. Recurrent disease was defined 
as locoregional, distant, or both and was histologically con-
firmed whenever possible.
Definition of Efficacy End Points
Response to preoperative chemotherapy was assessed 
symptomatically, clinically, and pathologically. A symptom-
atic response was defined as an improvement or resolution 
of dysphagia. Clinical response was assessed by comparing 
the initial EUS obtained during staging with the preoperative 
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EUS obtained after the completion of induction chemother-
apy. A clinical complete response was defined by resolution 
of all visible disease. A partial response was defined as any 
improvement in the clinically determined T or N descriptor 
without a reciprocal deterioration in N or T. Resolution of 
M1a disease was also considered a partial response. Stable 
disease was defined as no change in the clinical tumor, node, 
and metastasis assignments. Progressive disease was therefore 
defined as any increase in the clinical T or N descriptors.
Pathologic response was based on a comparison of the 
surgical specimen with the initial staging EUS. A complete 
pathologic response was defined as total disappearance of all 
viable diseases. Similar to the clinical response assessment, a 
partial pathologic response was defined as any improvement 
in the pathologic T or N descriptor (without reciprocal dete-
rioration in N or T) when compared with the initial clinical 
stage. Pathologic stable disease and progressive disease was 
defined as no change in the T or N descriptors or any increase 
in the pathologic T or N descriptors, respectively. Pathologic 
response was also separately assessed as the residual viabil-
ity, defined as the percentage of residual viable tumor in com-
parison to fibrosis and acellular mucin pools. The degree of 
residual tumor viability was determined by the pathologist and 
for analysis purposes was categorized as less than 25%, 25% 
to 49%, 50 to 75%, and more than 75%.
Statistical Considerations
The primary feasibility end point was the rate of resec-
tion after induction chemotherapy. A resection rate of more 
than or equal to 88% was sought and less than or equal to 
75% was deemed unacceptable. Enrollment of 60 patients was 
required to demonstrate this rate of resection with 82% power 
and a significance of 5%. The secondary feasibility end point 
was the ability to complete postoperative chemoradiotherapy. 
This regimen would be deemed unacceptable if less than 
or equal to 65% of resected patients were able to complete 
postoperative treatment. We anticipated 53 patients would 
be evaluable for this end point, with 75% power to detect 
more than or equal to 80% ability to complete postoperative 
chemoradiotherapy.
Standard descriptive statistics were used to summarize 
patient and treatment characteristics. Outcomes were calcu-
lated from the treatment initiation date until the date of the 
event corresponding to each outcome, or the date of last fol-
low-up. Outcomes of interest included recurrence-free sur-
vival (RFS) defined by the events of death from any cause, or 
any local, regional or distant disease recurrence; OS, defined 
by death from any cause; locoregional control (LRC) defined 
by recurrence at the primary site or in regional lymph nodes; 
and distant metastatic control (DMC), defined by recurrence 
in a distant site. Outcomes were estimated using the Kaplan-
Meier method and compared with other study variables using 
the log-rank test. Stepwise Cox proportional hazards analysis 
with a variable entry criterion of p less than 0.10 and a vari-
able retention criterion of p less than 0.05 was used to identify 
multivariable prognostic factors. Cox results were summa-
rized as the hazard ratio (HR) and 95% confidence interval 
(CI) for HR. Analyses were conducted using SAS software 
(SAS Institute, Inc., Cary, NC). Unless otherwise noted, all 
statistical tests were two-sided, and p less than 0.05 was used 
to indicate statistical significance.
RESULTS
Patient Characteristics
Between February 2008 and January 2012, 61 patients 
were enrolled on this protocol. One patient withdrew consent 
before receiving any treatment and is not included in this 
analysis, resulting in an eligible and evaluable cohort of 60 
patients. Table 1 details the characteristics of these 60 patients. 
The majority were Caucasian males with tumors located at the 
GEJ. All patients had either T3-4 or N1 tumors. There were 15 
patients (25%) who had clinical M1a disease (American Joint 
Committee on Cancer 6th edition).
Feasibility
Resection with curative intent was accomplished in 54 
patients (90%) confirming the feasibility of this induction 
regimen. The six patients (10%) who did not undergo a poten-
tially curative resection on this trial included one patient who 
died during induction, one patient taken off study because of 
induction-related toxicity, and four patients who were found to 
be unresectable due to either locoregional disease progression 
(three patients) or metastatic disease (one patient). Adjuvant 
chemoradiotherapy was administered to 48 patients (80%), 
further confirming the feasibility of this schedule. There were 
TABLE 1.  Patient and Tumor Characteristics (N = 60)
Patients Number (%) Patients Number (%)
No. of patients 60 Tumor location
Enrolled: February  
2008–January 2012
Mid-esophagus 2 (3)
Distal esophagus 11 (18)
GEJ 47 (78)
Median age 60 (37–75) years Clinical stage
Eastern Cooperative  
Oncology Group 
T2 3 (5)
  0 40 (67) T3 56 (93)
  1 20 (33) T4 1 (2)
Gender
  Male 57 (95) N0 22 (37)
  Female 3 (5) N1 38 (63)
Race
  Caucasian 58 (97) M0 45 (75)
  African American 2 (3) M1a 15 (25)
Differentiation Clinical stage
  Mod/well 15 (25) T3N0 22 (37)
  Poor 34 (57) T2N1 3 (5)
  NOS 11 (18) T3N1 19 (32)
Barrett’s esophagus
  Yes 21 (35) T4N1 1 (2)
  No 39 (65) T3N1M1a 15 (24)
GEJ, gastroesophageal junction.
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six patients (10%) who underwent surgery but did not begin 
adjuvant therapy. Reasons for this included delayed healing/
postoperative complications (two patients), postoperative 
deaths (two patients), and the early development of progres-
sive disease (two patients).
Toxicity
Table 2 details the most frequently encountered toxicities 
of this multimodality regimen. During induction chemother-
apy, diarrhea, mucositis, hand-foot syndrome, and asymptom-
atic neutropenia were the most often encountered toxicities 
and were the most frequent reasons for dose modification. 
Unplanned hospitalization was required in 18% of patients and 
was most often attributed to dehydration from diarrhea and 
mucositis. Febrile neutropenia was uncommon. Two patients 
did not complete induction therapy. One died suddenly at 
home, early during the treatment course of unknown cause. 
The second was taken off study after developing profound gas-
trointestinal ileus during the first course of induction therapy.
Postoperative complications occurred in 24 patients 
(44%). The most common complications were chylothorax 
(17%), pneumonia (17%), and wound infections (21%). Two 
patients died in the postoperative period. One patient devel-
oped acute respiratory failure of undetermined etiology 2 days 
after surgery. This progressed to acute respiratory distress syn-
drome  and the patient subsequently died of a gastrointestinal 
hemorrhage 3 weeks after surgery. The second patient died 
suddenly at home 2 weeks after an uncomplicated surgery.
During adjuvant chemoradiotherapy, myelosuppres-
sion, nausea, and vomiting were the most often encountered 
toxicities. Overall, unplanned hospitalization was required 
in 19% of patients during adjuvant therapy, often a result of 
febrile neutropenia, which was more common during adjuvant 
therapy than during the induction regimen. Other reasons for 
unplanned hospitalization included dehydration, pulmonary 
embolism, and congestive heart failure.
Protocol-defined dose modifications were frequently 
required during preoperative chemotherapy because of 
anticipated toxicities. During induction therapy, the majority 
of patients received the full dose of epirubicin and oxali-
platin, with 90% of patients receiving more than or equal 
to 80% dose intensity (DI). However, only 47% of patients 
received more than or equal to 80% of induction 5FU DI. 
This was largely attributable to gastrointestinal toxicity 
(mucositis and diarrhea) and asymptomatic neutropenia. 
Most patients received the full planned dose of cisplatin and 
5FU during adjuvant chemoradiotherapy. However, seven 
patients received only one cycle of adjuvant treatment (50% 
of the planned dose), most often due to clinical deteriora-
tion, progressive disease, or inadequate hematologic recov-
ery. Overall, 85% of patients received more than or equal to 
80% adjuvant chemotherapy DI.
Response to Induction Chemotherapy
The response to induction therapy is detailed in Table 3. 
The majority of patients achieved either improvement or reso-
lution of dysphagia, which defined a symptomatic response to 
the induction regimen. Clinical (EUS) and pathologic down-
staging was observed less frequently. Although complete 
pathologic responses were seen in only a few patients, there 
appeared to be a continuum of pathologic regression as deter-
mined by residual viability.
Upon pathologic review, surgical margins were involved 
in 18% of patients; circumferential margin in 15%, distal mar-
gin in 9%, and the proximal margin in 2%. The mean number 
of retrieved lymph nodes was 34 (range: 7–69), of which the 
mean number of positive lymph nodes was 4 (range: 0–44).
Survival and Patterns of Recurrence
With a median follow-up of 43 months, the Kaplan-
Meier projected 3-year RFS is 41% and OS is 47% with a 
median of 19 and 27 months, respectively (Figure 1A, B). 
There were 29 patients (48%) who have developed distant 
metastases and 4 (7%) who have experienced a locoregional 
failure, with a Kaplan-Meier projected 3-year DMC and LRC 
rate of 46% and 88%, respectively. The median DMC is 25 
months, whereas the median LRC has not been observed 
(Figure 1C, D). The most common sites of first distant failure 
included the liver (34%), lung (17%), and peritoneum (24%).
Clinical features that were found to be prognostic for 
DMC, RFS, and OS on univariate analysis included the symp-
tomatic response after induction therapy, the status of the cir-
cumferential margin, and the amount of residual viable tumor 
identified in the surgical specimen (Figure 2 and Table 4).
Multivariate analysis confirmed the importance of resid-
ual tumor viability as an independent prognostic factor for 
survival. OS decreased for every 10% increase in the residual 
viability (HR 1.38 [1.18–1.62], p < 0.001). As in the univari-
ate analysis, symptomatic response to the induction regimen 
was prognostic for improved survival (HR 3.45 [1.60–7.42], 
p = 0.002) in multivariable analysis when considering baseline 
and response variables, but was not significant once patho-
logic outcomes including viability were included.
DISCUSSION
This treatment protocol was designed to increase che-
motherapy exposure in a patient population at high risk for 
distant failure. It was also anticipated that the potential ben-
efit of concurrent chemoradiotherapy on LRC could be main-
tained despite deferring this therapy to the adjuvant setting. 
Using chemoradiotherapy in the postoperative setting would 
TABLE 2.  Toxicity (N = 60 for Preoperative Therapy, N = 48 
for Adjuvant Therapy)
Toxicity
Preoperative 
Therapy (%)
Postoperative 
Therapy (%)
Nausea/emesis (≥grade 3) 8 10
Mucositis/esophagitis (≥grade 3) 13 2
Diarrhea (≥grade 2) 28 6
Hand-foot syndrome (≥grade 2) 15 2
ANC < 1000/μl 32 27
Febrile neutropenia 2 10
Platelets <50,000/μl 0 21
Unplanned hospitalization 18 19
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also avoid the potential morbidity associated with surgery in 
a recently irradiated patient. Our schedule proved feasible and 
the toxicity was acceptable. Approximately 90% of enrolled 
patients underwent curative intent surgery and 80% received 
adjuvant chemoradiotherapy.
It is important to stress how difficult it is to compare 
outcomes between different phase II and phase III trials con-
ducted in different patient populations, using different treat-
ment regimens. We have also previously noted how important 
known prognostic features are in influencing ultimate patient 
outcomes.17 Overall, however, the Kaplan-Meier 3-year pro-
jected OS of 47% in this trial compares favorably with the 
outcomes of other multimodality treatment schedules in this 
disease.2,3,5,6
Given the morbidity of esophagectomy and its modest 
curative potential, the identification of clinical markers prog-
nostic for favorable treatment outcomes would be very use-
ful. In our study, clinical response, defined by EUS performed 
before and after induction therapy, did not correlate with RFS 
or OS. This finding is consistent with the published literature 
and further suggests that repeated clinical staging with EUS 
after induction chemotherapy does not offer meaningful prog-
nostic information.18–22 Alternatively, symptomatic response 
to induction therapy, defined as an improvement or resolu-
tion of dysphagia, correlated closely with residual viability, 
TABLE 3.   Response to Induction Therapy (N = 58 for 
Symptomatic and Clinical Response, N = 54 for Pathologic 
Response and Residual Tumor Viability)
Symptomatic 
(Dysphagia) Response % Pathologic Response %
  Resolved 79 Complete response 5
  Improved 10 Partial response 36
  Stable 3 Stable disease 24
  Worse 7 Progressive disease 34
Clinical (EUS) 
response
% Residual tumor viability %
  Partial response 48 <25% 17
  Stable disease 33 25–49% 22
  Progressive disease 19 50–75% 44
>75% 17
EUS, endoscopic ultrasound.
FIGURE 1.  Kaplan-Meier projections for the study population. A, Overall survival; (B) recurrence-free survival; (C) distant meta-
static control; (D) locoregional control.
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DMC, RFS, and OS. In practice, this improvement is often 
noted within 1 to 2 weeks of starting treatment. Patients with 
unimproved dysphagia after induction are a poor prognostic 
group and experience only limited benefit from surgery. This 
relatively simple assessment may be as accurate in providing 
prognostic information regarding treatment outcomes as any 
more invasive, expensive, or sophisticated procedures.
It has been repeatedly noted that patients who achieve 
a complete pathologic response to preoperative chemoradio-
therapy have a significantly improved OS.6,23–25 This has led 
other investigators to intensify preoperative treatment with 
the goal of increasing the pathologic complete response rate. 
Preoperative chemotherapy alone is less likely to sterilize pri-
mary site disease and as such has not been widely adopted. 
We suggest that it is not the completeness of the response to 
chemoradiotherapy that is most important, but the responsive-
ness of the tumor to chemotherapy alone. Although excellent 
locoregional disease control can be obtained with the com-
bination of surgery and chemoradiotherapy, these patients 
predominately experience distant failure, for which the goal 
of increasing exposure to effective systemic chemotherapy 
seems the most logical approach. Thus, although the patients 
in our study who achieved a complete response had excellent 
outcomes, these patients were infrequent. Even partial patho-
logic regression to induction chemotherapy was important, 
however, and was closely associated with DMC, RFS, and OS. 
In both univariate and multivariate analyses, residual viability 
was a significant prognostic factor for survival outcomes.
In conclusion, treatment with induction chemother-
apy, surgery, and postoperative chemoradiotherapy appears 
FIGURE 2.  Kaplan-Meier projections based on residual viability. A, Overall survival; (B) recurrence-free survival.
TABLE 4.  Univariable Prognostic Factors
Variable
Distant Metastatic Control Overall Survival Recurrence-Free Survival
HR 95% CI p HR 95% CI p HR 95% CI p
Clinical response
  SD + PD/PR 2.13 0.99–4.59 0.06 1.58 0.78–3.2 0.21 1.59 0.80–3.15 0.18
Symptomatic response
  Unresolved/resolved 3.75 1.68–8.38 0.001 3.45 1.6–7.42 0.002 3.32 1.56–7.04 0.002
Pathologic response
  SD + PD/CR + PR 2.70 1.15–6.32 0.023 1.82 0.86–3.84 0.12 1.78 0.86–3.65 0.12
Circumferential margin
  Positive/negative 5.50 2.22–13.6 <0.001 3.72 1.53–9.03 0.004 4.0 1.66–9.62 0.002
Viable tumor
  Per 10% increase 1.29 1.11–1.5 0.001 1.22 1.07–1.4 0.004 1.26 1.1–1.44 <0.001
Angiolymphomatic invasion
  Yes/no 2.76 1.15–6.62 0.023 2.19 0.99–4.86 0.06 2.12 0.99–4.55 0.06
Tumor length
  Per 1-cm increase 0.92 0.77–1.11 0.41 0.90 0.75–1.07 0.22 0.90 0.76–1.06 0.20
Tumor location
  Esophagus/GEJ 1.87 0.85–4.1 0.12 1.49 0.69–3.22 0.31 1.42 0.66–3.02 0.37
GEJ, gastroesophageal junction; HR, hazard ratio; CI, confidence interval.
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feasible and tolerable. This treatment schedule resulted in 
excellent LRC and comparable survival outcomes to other 
perioperative treatment approaches. This relatively intense 
treatment regimen, however, significantly prolongs the dura-
tion of therapy, and distant failure still remains a common 
problem. Symptomatic improvement and less residual viable 
tumor at surgery appear to be of important prognostic value, 
and should be considered in future study design. Alternative 
treatment strategies need to be investigated for patients who 
fail to respond to induction therapy.
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